Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This medication helps improve lung function and oxygenation, often administered via endotracheal tube.

Curosurf is primarily used to manage respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs are not fully developed and lack sufficient surfactant, a substance that keeps the air sacs open. By providing exogenous surfactant, Curosurf helps to reduce surface tension in the lungs, facilitating easier breathing and improving oxygen levels. It is typically administered directly into the lungs via an endotracheal tube.

Curosurf works by replacing the natural surfactant in the lungs, which helps to reduce the effort required to breathe. This can lead to improved oxygenation and reduced need for mechanical ventilation in premature infants. The effects are generally observed shortly after administration, with improvements in lung function and respiratory stability.

Curosurf should be administered by healthcare professionals experienced in neonatal intensive care. It is important to monitor the infant closely for any signs of adverse reactions. The medication should be stored and handled according to the manufacturer's guidelines to ensure its efficacy and safety.

Curosurf is generally used in a controlled clinical setting where interactions with other medications are carefully monitored. However, it is important to inform healthcare providers about any other medications the infant may be receiving to avoid potential complications. Always follow the advice of a healthcare professional regarding the use of Curosurf.